Cambridge Healthtech Institute’s 2nd Annual

Biologics for Autoimmune Diseases

New Science and Technology to Empower the Next Wave of Autoimmunity Therapeutics

May 11-12, 2026

 

Autoimmune disorders present enormous diversity in pathology and patient response, demanding equally diverse therapeutic approaches. The Biologics for Autoimmune Diseases conference will showcase how next-generation biologics are being designed to meet that challenge across musculoskeletal, skin, gut, and systemic indications. Sessions will cover engineered Treg and T cell therapies, novel antibody and multispecific formats, and innovative delivery strategies for diseases like rheumatoid arthritis, psoriasis, Crohn’s disease, and rare autoimmune syndromes. Attendees will also see how AI-driven design, translational models, and multiomics integration are shaping drug discovery and patient stratification. By drawing on lessons from oncology, this track highlights emerging modalities, safety engineering, and mechanism-focused innovations that are redefining immune tolerance and reshaping treatment possibilities for autoimmune diseases.

 

Coverage will include, but is not limited to:

 

Targeting the Musculoskeletal System

  • Engineered Treg and T cell therapies for immune tolerance
  • Emerging engineered modalities
  • Leveraging multimodal therapies to address complex inflammatory pathways and heterogeneous patient responses
  • Novel strategies for RA, ankylosing spondylitis, and psoriatic arthritis
  • Sustained release and local delivery strategies

Targeting Skin

  • Advances in treating psoriasis, atopic dermatitis, and hidradenitis suppurativa therapies
  • Cell-based and tolerogenic approaches
  • Mechanism-focused innovations
  • Novel antibody and multispecific formats
  • Overcoming formulation and delivery challenges

Targeting the Gut

  • Clinical and preclinical updates
  • Delivery and stability strategies
  • Gaps and progress in Crohn’s disease, ulcerative colitis, and IBD
  • Novel therapeutic modalities and mechanism-focused strategies
  • T cell modulation and engineered cell therapies to induce tolerance in the gut

Other Autoimmune Indications

  • Cardiovascular and systemic autoimmunity
  • Neurological autoimmunity
  • Rare and emerging indications

Research Tools and Models

  • Advanced translational models
  • AI in drug design and optimization
  • Multiomics integration
  • Patient stratification and responder identification
  • PK/PD modeling and simulation

Learnings from Cancer

  • Checkpoint modulation
  • Engineering for safety and selectivity
  • Managing immunotherapy-induced autoimmunity
  • Next-gen modalities crossing over
  • Repurposing oncology biologics

 

The deadline for priority consideration is October 17, 2025.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 


For more details on the conference, please contact:

Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: 207-329-2964

Email: ksimmons@healthtech.com

 

For sponsorship information, please contact:

Companies A-K

Jason Gerardi

Sr. Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-5452

Email: jgerardi@healthtech.com

 

Companies L-Z

Ashley Parsons

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-972-1340

Email: ashleyparsons@healthtech.com


Submit a Speaker Proposal

View By:


Premier Sponsors

FairJourneyBiologics GenScript-CRO Integral-Molecular_NEW   Nona_Biosciences_NEW